SAN DIEGO, May 3, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc., ("Apricus Bio") (Nasdaq:APRI) today announced that Edward Cox, Vice President, Corporate Development and Investor Relations, was recently interviewed by "Steve Crowley's American Scene," a radio broadcast on the Money Channel, produced by IRNUSA News. To access the interview, go to:
During the interview, Mr. Cox highlighted Apricus Bio's latest achievements as compared to those of October 29, 2011, the date of the Company's last interview with Steve, including, among others:
- the approval of the Company's first product, Vitaros® for the treatment of erectile dysfunction, in Canada;
- the further development of the other 12 products and product candidates across a range of indications, currently in the Company's pipeline;
- a 225% increase in the Company's current market capitalization; and
- the securing of strong cash reserves into Q3 2012 based on current Company projections
In addition, according to Mr. Cox, Apricus Bio is looking to further license and commercialize Vitaros® for erectile dysfunction with corporate partners in numerous major international markets. The Company is also focused on the development of other of its late stage products based on its flexible, proprietary NexACT® technology.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals, among others.
For further information on Apricus Bio, visit and for information on its subsidiaries please visit or . You can also receive information at and .
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further development products and product candidates, to have its products and product candidates approved by relevant regulatory authorities, to successfully commercialize such products and product candidates and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT: Apricus Biosciences, Inc. Edward Cox, V.P. Corporate Development & Investor Relations, Apricus Biosciences, Inc. (858) 848-4249 ecox@apricusbio.com Apricus Bio Investor Relations Paula Schwartz Rx Communications Group, LLC (917) 322-2216 pschwartz@rxir.com
